Champions Oncology, Inc. (CSBR): Cost of Revenue
$30.90M
Year ended 2026-04-30
$30.44M
Trailing 12 months to 2026-07-31
+1.5%
3-year compound annual growth
+7.6%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2026-04-30 | $30.90M | +8.8% | 2026-07-27, From 2025-05-01 |
| 2025-04-30 | $28.39M | -3.4% | 2026-07-27, From 2024-05-01 |
| 2024-04-30 | $29.40M | -0.4% | 2025-07-23, From 2023-05-01 |
| 2023-04-30 | $29.53M | +25.0% | 2024-07-19, From 2022-05-01 |
| 2022-04-30 | $23.63M | +10.2% | 2023-07-24, From 2021-05-01 |
| 2021-04-30 | $21.45M | +26.2% | 2022-07-22, From 2020-05-01 |
| 2020-04-30 | $17.00M | n/a | 2021-07-26, From 2019-05-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $30.90M | +8.8% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $26.99M | +11.0% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $26.0K | -96.9% |
| Compugen Ltd (CGEN) | 2025-12-31 | $9.25M | +16.7% |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $70.95M | +56.8% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $96.37M | +746.3% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $39.21M | -16.7% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $5.76M | +622.3% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $753.0K | n/a |
Compare CSBR, PLX, VIR, CGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗